Several miRs exert antitumor effects by targeting HMBG1 in breast cancer cells: miR-107 has been shown to inhibit the autophagy, growth, and migration of these cells in vitro and in vivo [76], and miR-205 has been shown to decrease the viability and acquisition of TN breast cancer cells in the EMT phenotype by partially targeting the HMGB1-RAGE signaling pathway [77]. This evidence concerns the gene HMGB1 and breast carcinoma.